Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Rebetol Available In Italy For Use With Interferon Alfa-2b In Chronic Hepatitis NEW YORK, N.Y. -- October 19, 1999 -- ICN Pharmaceuticals, Inc. said today that its licensing partner Schering-Plough Corporation has commenced sales in Italy of its Rebetol® (ribavirin) Capsules for use in combination with Schering-Plough’s interferon alfa-2b injection for the treatment of both relapsed and previously untreated chronically infected hepatitis C patients. Sales in Italy of Rebetol® follow its launch in Germany and the United Kingdom earlier this year. Italy has one of the highest rates of hepatitis C prevalence in the European Union (EU), and the country historically has been the largest commercial market for hepatitis C treatments in the EU. The European Commission’s approval of Rebetol in May resulted in a single Marketing Authorization with unified labeling that is valid in all 15 European Union member States. "The continued expansion of this new therapy in the European Union is good news for patients with hepatitis C," said Milan Panic, Chairman and Chief Executive Officer of ICN Pharmaceuticals, which discovered ribavirin (ICN’s trademark Virazole®). "Proven to be substantially more effective than previous treatment options, combination therapy has become the treatment of choice in both Europe and the United States." As many as five million people in Western Europe are chronically infected with the hepatitis C virus, according to the World Health Organization. The infection is the leading cause of liver disease in Western Europe and the most common reason for liver transplant. Schering-Plough has exclusive worldwide rights to market oral ribavirin for hepatitis C under a license from ICN. Ribavirin is a synthetic nucleoside analog with broad-spectrum antiviral activity, currently marketed by ICN as Virazole® in a variety of other dosage forms for at least one of 10 indications in 44 countries. In the United States, Schering-Plough markets Rebetron™ Combination Therapy containing Rebetol® (ribavirin, USP) Capsules and Intron® A (interferon alfa-2b, recombinant) Injection for the treatment of chronic hepatitis C. It also markets the combination therapy in Canada and Argentina. Some four million Americans are infected with the hepatitis C virus, according to the Centers for Disease Control and Prevention (CDCP). Related Links: ICN Pharmaceuticals, Inc. and Schering-Plough Corporation. E-mail this page to a friend or colleague! To print, use this version